PMID: 2125153Dec 1, 1990Paper

Five year results of a 3-month and two 5-month regimens for the treatment of sputum-positive pulmonary tuberculosis in south India

Tubercle
R BalasubramanianP R Somasundaram

Abstract

A controlled study of three short-course regimens was undertaken in South Indian patients with newly diagnosed, sputum-positive pulmonary tuberculosis. The patients were allocated at random to one of three regimens: a) Rifampicin, streptomycin, isoniazid and pyrazinamide daily for 3 months (R3); b) the same regimen as above but followed by streptomycin, isoniazid and pyrazinamide twice-weekly for a further period of 2 months (R5); c) the same as R5 but without rifampicin (Z5). A bacteriological relapse requiring treatment occurred by 5 years in 16.8% of 113 R3, 5.2% of 97 R5, and 20.0% of 115 Z5 patients with organisms sensitive to streptomycin and isoniazid initially. The differences in the relapse rates between the R3 and R5 regimens and the R5 and Z5 regimens were statistically significant (p less than 0.01 for both). Considering patients with organisms initially resistant to streptomycin or isoniazid or both, 7 of 52 patients (4 R3, 2 R5, 1 Z5) had a bacteriological relapse requiring retreatment.

Citations

Aug 31, 1991·Lancet·J L StanfordA Pozniak
Aug 1, 1994·International Journal of Antimicrobial Agents·V St Georgiev
May 22, 2003·Tuberculosis·P R NarayananP Paul Kumaran
Jun 28, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Eline L KorenrompPaul Nunn
Jan 1, 1996·Annual Review of Microbiology·G A Rook, R Hernandez-Pando
Apr 14, 2000·American Journal of Respiratory and Critical Care Medicine·R S WallisJ J Ellner
Jun 23, 2009·American Journal of Respiratory and Critical Care Medicine·John L JohnsonW Henry Boom
Aug 16, 2006·American Journal of Respiratory and Critical Care Medicine·Kwok C ChangCheuk M Tam
Feb 17, 2001·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·K A HarrisM K Lalitha
Dec 1, 1990·Tubercle·J M Grange
Jan 29, 2014·The Cochrane Database of Systematic Reviews·Anuradha BosePrathap Tharyan
May 5, 2000·The Cochrane Database of Systematic Reviews·H Gelband
Mar 13, 2003·Tropical Medicine & International Health : TM & IH·M BiotJ D H Porter
Oct 30, 1999·Antimicrobial Agents and Chemotherapy·R S WallisJ J Ellner

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.